Beta-Pro is a Biotechnology, Cellular Services Company for Diabetes Research
The mission of Beta-Pro is to facilitate a cure for diabetes by establishing a sustainable source
and distribution network of customized in vitro cellular services for use in regenerative
medicine and cell replacement therapies, drug discovery and molecular/cellular
research.
Beta-Pro accomplishes this
mission
by:
- Expanding knowledge of human islet cell biology
- Harvesting donor organs that are not suitable for transplantation
- Providing in vitro islet
cell cultures for biomedical research
- Developing technologies to preserve islet
cells post-transplant
- Improving islet cell processing techniques
- Improving islet
cell culture and expansion
- Improving non-invasive cellular imaging in vivo
- Developing
new sources of insulin-producing, glucose-responsive cells
- Providing screening services to find potent biochemical compounds enhancing functions
of pancreatic islets
- Providing cellular materials from normal and diseased human islets for molecular/cellular
biological research against diabetes
- Conducting research and development on islet biology and stem cell biology
Cellular Services and Cellular Therapy Offer Hope for Regenerative Medicine
We believe cellular therapy now offers people with diabetes and other medical conditions
a chance to reverse disease. That is why university research laboratories, contract
research corporations, pharmaceutical companies, and medical institutions with cellular
transplant programs are interested in our custom islet cells and in vitro cellular services.
Screening Services Provide Opportunities for Drug Discovery of Diabetes Therapy
Enhancing the insulin-producing ability of pancreatic islets using bioactive compounds
is a potential way to ameliorate diabetes, especially type-2 diabetes. Islet cell-based
screening is a perfect platform for discovering such compounds as potential diabetes
drugs. Beta-Pro develops a system to detect glucose stimulated insulin secretion
(GSIS) by normal and diseased human islets at a screening scale. The service will
facilitate proprietary diabetes drug discovery.
Cellular Materials From Normal and Diabetic Human Islets are Invaluable for
Exploring New Molecular Mechanisms of Action Against Diabetes
According to a report of The National Institute of Diabetes and Digestive and Kidney
Diseases (NIDDK), research that seeks the elucidation of molecular structures or
biological pathways may lead to the identification and validation of targets that
can be potentially manipulated by ligands/inhibitors, "Druggable" molecular targets/pathways.
In serving this purpose, BetaPro provides sets of cellular materials, including
total RNA, protein lysate, and histological sections obtained from normal and disease
donors for molecular and cellular biological research.
|